168 related articles for article (PubMed ID: 19233434)
1. Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the M. D. Anderson Cancer Center experience with (125)iodine brachytherapy.
Frank SJ; Levy LB; Kuban DA; Lee AK; Kudchadker RJ; Bruno TL; van Vulpen M; Swanson DA
J Urol; 2009 Apr; 181(4):1658-63; discussion 1663-4. PubMed ID: 19233434
[TBL] [Abstract][Full Text] [Related]
2. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
[TBL] [Abstract][Full Text] [Related]
3. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
4. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
5. The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy.
Potters L; Huang D; Fearn P; Kattan MW
Brachytherapy; 2003; 2(1):26-31. PubMed ID: 15062160
[TBL] [Abstract][Full Text] [Related]
6. Surgery versus implant for early prostate cancer: results from a single institution, 1992-2005.
Colberg JW; Decker RH; Khan AM; McKeon A; Wilson LD; Peschel RE
Cancer J; 2007; 13(4):229-32. PubMed ID: 17762756
[TBL] [Abstract][Full Text] [Related]
7. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
[TBL] [Abstract][Full Text] [Related]
8. Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: a review of the H. Lee Moffitt Cancer Center experience.
Torres-Roca JF; Cantor AB; Shukla S; Montejo ME; Friedland J; Seigne JD; Heysek R; Pow-Sang J
Urol Oncol; 2006; 24(5):384-90. PubMed ID: 16962486
[TBL] [Abstract][Full Text] [Related]
9. Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation.
Wong WW; Buskirk SJ; Schild SE; Prussak KA; Davis BJ
J Urol; 2006 Nov; 176(5):2020-4. PubMed ID: 17070243
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy.
Joseph J; Al-Qaisieh B; Ash D; Bottomley D; Carey B
BJU Int; 2004 Dec; 94(9):1235-8. PubMed ID: 15610096
[TBL] [Abstract][Full Text] [Related]
11. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
Beyer DC; McKeough T; Thomas T
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1299-305. PubMed ID: 15817331
[TBL] [Abstract][Full Text] [Related]
12. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience.
Sylvester JE; Grimm PD; Blasko JC; Millar J; Orio PF; Skoglund S; Galbreath RW; Merrick G
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):57-64. PubMed ID: 17084544
[TBL] [Abstract][Full Text] [Related]
13. Perineural invasion on prostate needle biopsy does not predict biochemical failure following brachytherapy for prostate cancer.
Weight CJ; Ciezki JP; Reddy CA; Zhou M; Klein EA
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):347-50. PubMed ID: 16545922
[TBL] [Abstract][Full Text] [Related]
14. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer.
Potters L; Morgenstern C; Calugaru E; Fearn P; Jassal A; Presser J; Mullen E
J Urol; 2005 May; 173(5):1562-6. PubMed ID: 15821486
[TBL] [Abstract][Full Text] [Related]
15. Low predictive accuracy of the Kattan postoperative nomogram for renal cell carcinoma recurrence in a population of French patients.
Hupertan V; Roupret M; Poisson JF; Chretien Y; Dufour B; Thiounn N; Mejean A
Cancer; 2006 Dec; 107(11):2604-8. PubMed ID: 17075871
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy.
Pickles T;
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1355-9. PubMed ID: 16406391
[TBL] [Abstract][Full Text] [Related]
17. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019.
Lee WR; Bae K; Lawton C; Gillin M; Morton G; Firat S; Baikadi M; Kuettel M; Greven K; Sandler H
Cancer; 2007 Apr; 109(8):1506-12. PubMed ID: 17340591
[TBL] [Abstract][Full Text] [Related]
18. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):669-77. PubMed ID: 16682149
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer.
Kattan MW; Zelefsky MJ; Kupelian PA; Cho D; Scardino PT; Fuks Z; Leibel SA
J Clin Oncol; 2003 Dec; 21(24):4568-71. PubMed ID: 14673043
[TBL] [Abstract][Full Text] [Related]
20. Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer.
Merrick GS; Galbreath RW; Butler WM; Waller KE; Allen ZA; Lief J; Adamovich E
Cancer; 2007 Jul; 110(2):289-96. PubMed ID: 17549691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
